Pharming Group N.V. (ENXTAM:PHARM) is looking acquisitions. During the company?s first half 2023 results call, Jeroen Wakkerman, Chief Financial Officer said that ?We continue to look at investments on acquisitions and in-licensing of mid- to late-stage opportunities in rare diseases to build the company further?.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7675 EUR | +1.32% |
|
+1.72% | -25.56% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.56% | 545M | |
+54.61% | 811B | |
+43.45% | 640B | |
-6.33% | 353B | |
+20.62% | 333B | |
+10.44% | 302B | |
+17.91% | 246B | |
+2.41% | 225B | |
+12.64% | 218B | |
+8.61% | 168B |
- Stock Market
- Equities
- PHARM Stock
- News Pharming Group N.V.
- Pharming Seeks Acquisitions